Back

Cerebrospinal fluid 2-hydroxyglutarate (2-HG) as a monitoring biomarker for IDH-mutant gliomas

Riviere-cazaux, C.; Lacey, J. M.; Carlstrom, L. P.; Laxen, W. J.; Munoz-Casabella, A.; Hoplin, M. D.; Ikram, S.; Bin Zubair, A.; Andersen, K. M.; Warrington, A. E.; Decker, P. A.; Kaufmann, T. J.; Campian, J. L.; Eckel-Passow, J. E.; Kizilbash, S. H.; Tortorelli, S.; Burns, T. C.

2023-03-02 oncology
10.1101/2023.03.01.23286412 medRxiv
Show abstract

D-2-hydroxyglutarate (D-2-HG) is a well-established oncometabolite of isocitrate dehydrogenase (IDH) mutant gliomas. While prior studies have demonstrated that D-2-HG is elevated in the cerebrospinal fluid (CSF) of patients with IDH-mutant gliomas1,2, no study has determined if CSF D-2-HG can provide a plausible method to evaluate therapeutic response. We are obtaining CSF samples from consenting patients during their disease course via intra-operative collection and Ommaya reservoirs. D-2-HG and D/L-2-HG consistently decreased following tumor resection and throughout chemoradiation in patients monitored longitudinally. Our early experience with this strategy demonstrates the potential for intracranial CSF D-2-HG as a monitoring biomarker for IDH-mutant gliomas.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.